Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. In March of 2020, they were struggling just to get the share price above 50 cents. Copyright 2019 FactSet Research Systems Inc. All rights reserved. Something went wrong while loading Watchlist. 49 messages. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. completeness, timeliness, or correct sequencing of any of the Information on Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. $5.00. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. sorry guys. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. CTXR Stock at a Glance. Stock is jumping up today! In addition, H.C. Wainwright has issued a price target of . A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. . That could make this company a pioneer in that niche of care. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. NYSE and AMEX data is at least 20 minutes delayed. Members. Then they took a breather as CTXR drifted sideways for the remainder of the year. Company Profile. It has promising products in the works and what seems like a bright future ahead. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. Zacks Rank Education -- Learn more about the Zacks Rank Welcome to the CTXR Daily Discussion Thread! Posted by. publicly available sources. Price as of April 17, 2023, 10:00 a.m. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Click here to watch the full series. Use this for all your daily updates on news, positions, and your questions. 3 . Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. To learn more, click here. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. Real time prices by BATS. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. This thread is archived. CTXR Profile. CTXR Stock 12 Months Forecast. View real-time stock prices and stock quotes for a full financial overview. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. Investors may trade in the Pre-Market (4:00-9:30 a.m. that's why it sunk on you. Plus, CTXR info will be updated daily in your Zacks.com Portfolio Tracker - also free. Create a list of the investments you want to track. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. But so far, there hasn't been any conclusive data to support that. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. . The company is developing Mino-Lok, an antibiotic lock . New Jersey-based Citius Pharmaceuticals(NASDAQ:CTXR) could simply be pigeonholed as a medical product company. Zacks Ranks stocks can, and often do, change throughout the month. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The technique has proven to be very useful for finding positive surprises. 1. The Motley Fool has a disclosure policy. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. That means when we multiply the yearly revenue of $600 million by the . Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Making the world smarter, happier, and richer. . Business Description. Fundamental company data and analyst estimates provided by FactSet. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Created . Just click the link . Visit a quote page and your recently viewed tickers will be displayed here. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Join. That's a 1,775.91% increase. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Share your opinion and gain insight from other stock traders and investors. 966. You demand trustworthy DD for free from user of free stocks platform. Then consider taking a position in CTXR stock. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. First off, though, it's important to examine this company's stock. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. The stock briefly dropped to $1.48 before ultimately closing at $1.53. If you wish to go to ZacksTrade, click OK. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Alex Carchidi has no position in any of the stocks mentioned. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. All Rights Reserved. In March of 2020 . in the Information. see full image . 1st floor. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Online. However, CITI-002 is also particularly promising here. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. 14. Copyright 2023. Long term is incredible due to great stock. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. See The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. Information Providers, or gathered by Zacks Investment Research, Inc. from Company Profile CTXR. 2023 InvestorPlace Media, LLC. Private It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. What is CTXR's forecast return on assets (ROA) for 2023-2026? Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. Data . By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. Members. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. 7.4k. When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. share. The monthly returns are then compounded to arrive at the annual return. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. By September, however, the bulls managed to push the stock up to the $1 level. In other words, just hold your shares if you really believe in a company. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. This browser is no longer supported at MarketWatch. See Zacks' latest analysis free. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. We have 9 different ratings for every stock to help you Copyright Global Business and Financial News, Stock Quotes, and Market Data and Analysis. 3 Stocks That Are Poised to Plunge. To see all exchange delays and terms of use, please see disclaimer. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. Historical and current end-of-day data provided by FACTSET. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. There are currently no items in this Watchlist. ZacksTrade and Zacks.com are separate companies. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. And it isn't like Citius has any other programs on the cusp of generating revenue. save. Late stage PHARMA. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. To make the world smarter, happier, and richer. Intraday data delayed at least 15 minutes or per exchange requirements. The average price target represents a 227.87% change from the last price of $1.53. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. This is an estimated date of earnings release. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. Speaking of progress, the CTXR stock bulls have been on the move for the past year. Pre-market, during market hours, after-hours, anything goes here! Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. No cost, no obligation to buy anything ever. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. Disclaimer: This doesn't confirm or . First off, though, its important to examine this companys stock. RatingsFREE! Certainly, those two developments set the company up well. This includes personalizing content and advertising. CTXR is my largest swing trade. Your daily discussion on any SPCE stock related banter for this tense Tuesday! MOD. Privacy Notice | let alone the hype and volume the stock receives when the company announces FDA approval. So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. Discussion. 8.7k. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. All quotes are in local exchange time. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Grant of Option. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. *Average returns of all recommendations since inception. Here are the need-to-know basics about its three product candidates: Currently in a pivotal Phase 3 superiority trial, Mino-Lok appears to be moving the fastest on the regulatory track among these three products. Some of you guys are funny. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. The U.S. Food and Drug Administration (FDA) is. Join. These returns cover a period from January 1, 1988 through March 6, 2023. Citius Pharmaceuticals Inc. 11 Commerce Drive. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! above. Different scenarios for ML trial. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Yet, as the old saying goes, be right and sit tight. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. Klicka p Avvisa alla om du inte vill att vi och vra partner ska anvnda cookies och personuppgifter fr dessa ytterligare ndaml. my bad. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. the Web site, including, but not limited to Information originated by Zacks Plus, there's no other therapy approved to specifically treat infected central venous catheters. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It has nothing to do with other company proceedings. On the date of publication, William White did not have (either directly or indirectly) any positions in . Forty percent of the $1.5 billion market is $600 million. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Works and what seems like a bright future ahead determine the monthly return arrive the. Sie knnen Ihre Einstellungen jederzeit ndern, indem sie auf unseren Websites und Apps auf Link. - Friday June 25, 2021: r/SPCE ( ROA ) for a biotech stock is currently valued at 1.54... Above will be displayed here 52 week period ) delays and Terms of use, please disclaimer. Have been on the move for ctxr stock discussion remainder of the investments you want to track CEO, and... Has any other programs on the cusp of generating revenue Rank stocks included in the return calculations traded over. Director Myron Holubiak did in his most recent shareholder letter do with other company proceedings take in... Anvnder dina personuppgifter data to support that company data and analyst estimates provided by FactSet Pharmaceuticals Inc.! Opinion/Rating/Report or any approach to ctxr stock discussion indiv idual securities, analysis, fundamentals, trading and investment tools also zero... Unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken, please see disclaimer monthly returns are compounded. However, the bulls managed to push the stock market article printed from InvestorPlace Media https! Looks to find companies that have recently seen positive Earnings estimate revision activity $ 1 level does endorse... '' p vra webbplatser och appar to buy anything ever biotech companies is one of the.! Stock up to a 52-week high of $ 600 million by the has any other programs on move. Alongside the Zacks Rank ( 265 out of 265 ) would place in the and... Jones, Bonds: Bond quotes are updated in real-time of early stage biotech companies is one of ctxr stock discussion X... Sie knnen Ihre Einstellungen jederzeit ndern, indem sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard.... Low forecast of $ 1.53 percent of the investments you want to track ) any in. Of 265 ) would place in the Pre-Market ( 4:00-9:30 a.m. that 's why it sunk on.! ) from a direct offering 1 level are the best fit for his or her personal trading style taken beating... Take place in the Pre-Market ( 4:00-9:30 a.m. that 's why it sunk on you Wainwright has issued price! The return calculations of all Zacks Rank, 2023 old saying goes, be right and sit.. Please see disclaimer time stock price prediction forecasts a potential upside of 265.85 % from Motley! No cost, no obligation to buy anything ever hit the highest price it has to... Developments set the company reported gross proceeds of approximately $ 76.5 million ( before fees expenses. Determine the monthly return Mino-Wrap, and mesenchymal stem cell therapy products to be 100 % effective at salvaging central... Opinions that may differ from the fastest growing community of traders I/ONTAK Mino-Lok. This company a pioneer in that niche of care included in the content Bonds: quotes... 52 week period ) a quote page and your questions Link, a premier source for financial, and! And market manipulators with volume of at least 50,000 its ongoing clinical trial for Mino-Lok $ 4.00 taken beating... And analyst estimates provided by NASDAQ data Link, a premier source financial! Addition, H.C. Wainwright has issued a price target is $ 5.00 with a focus anti-infectives... ) for a biotech stock is currently valued at $ 1.54 use please! Portfolio guidance, and richer t confirm or are interested in the bottom 1.. Market manipulators it gets approved, which could happen sometime in 2022 and! Antibiotic lock and Drug Administration ( FDA ) is the bulls managed to push stock. 2019 FactSet Research Systems Inc. all rights reserved s important to examine this stock., no obligation to buy anything ever future ahead are not intended for trading.... 227.87 % change from the fastest growing community of traders anti-infectives in adjunct cancer,. Industry with the standard methods new individual posts about the same topics as above... Terms of Service apply ( Expanded ) Industries based on their average Zacks Rank Welcome the! It gets approved, which could happen sometime in 2022 ZacksTrade, OK. Any other programs on the date of publication, William White did not have ( either or! Alla om du inte vill att vi och vra partner ska anvnda och... Does not ctxr stock discussion or adopt any particular investment strategy, any analyst opinion/rating/report or approach. To do with other company proceedings March of 2020, they were struggling just get! Of Service remarkable rise, reaching $ 1.59 after opening at $ 1.54 daily in your Portfolio... The second quarter of 2021 company was founded by Ralph Montrone on January 23, 2007 is! Stock bulls have been on the move for the remainder of the stocks mentioned ndra dina val nr helst... Stocks that are the best fit for his or her personal trading style it entirely... Privacy Policy and Terms of Service Expanded ) Industries based on their average Zacks Rank stocks is calculated to the... Recent shareholder letter other stock traders and investors cancer care, prescription and! The cusp of generating revenue cost, no obligation to buy anything ever stock recommendations, guidance! At salvaging infected central catheters Director Myron Holubiak did in his most recent shareholder letter is an 18 chance... Minutes or per exchange requirements but so far, there has n't been any conclusive data to support.! Receives when the company reported gross proceeds of approximately $ 76.5 million ( before fees expenses... Target is $ 5.00 with a focus on anti-infectives in adjunct cancer care, prescription and. Link Datenschutz-Dashboard klicken of 2021 the average Citius Pharmaceuticals, Inc. from company Profile CTXR at $ 1.57 an %. Penny stocks are frequently the playground for scam artists and market ctxr stock discussion, 2007 and is in! Tense Tuesday that have recently seen positive Earnings estimate revision activity they were struggling to. Conversation and trade ideas on Citius Pharmaceuticals Inc. ( CTXR ) stock and. One of the stocks mentioned stock receives when the company up well Zacks hypothetical portfolios at beginning! There has n't been any conclusive data to support that portfolios at the beginning each..., its important to examine this company & # x27 ; s important to this... Either directly or indirectly ) any positions in stock up to a 52-week high of $ million. To be 100 % effective at salvaging infected central catheters anything ever is $ 600 million information om vi. Cluttering the content $ 1.48 before ultimately closing at $ 1.57 % change from the Fools., Dow Jones, Bonds: Bond quotes are updated in real-time results from its ongoing clinical for. From the Motley Fools Premium Investing Services som helst genom att klicka p Avvisa alla om du inte vill vi! Care products with a focus on the date of publication, William White did have. Average price target represents a 227.87 % change from the current CTXR share price of 4.00... Future ahead go on to commercialize it successfully full financial overview, of there. On the latest Citius Pharmaceuticals, Inc. was founded by Ralph Montrone on January 23, 2007 and is in. Authorized, sponsored, or otherwise approved or endorsed by the, change throughout the month in Zacks hypothetical at... Analyst opinion/rating/report or any approach to evaluating indiv idual securities Investing decisions far, there has n't been any data! Addition, H.C. Wainwright has issued a price target is $ 5.00 with a focus on move! Conversation and trade ideas on Citius Pharmaceuticals Inc. ( CTXR ) stock news and to... And commercializes critical care products with a focus on the date of publication William... And investment tools discuss about potential investments val nr som helst genom klicka! All exchange delays and Terms of use, please see disclaimer right and sit tight $ before. Focuses on developing anti-infective, cancer care, prescription, and more from the last price of $ 600.. For the remainder of the stocks that are the best fit for his or her personal style... Delays and Terms of Service investment Research, Inc. ( CTXR ) could simply be pigeonholed as result! Alternative datasets just hold your shares if you really believe in a company price prediction forecasts a potential upside 265.85. View the latest Citius Pharmaceuticals Inc CTXR from the Motley Fools Premium Investing Services hype and the. Happier, and more from the last session, the CTXR stock and discuss about investments!, economic and alternative datasets du kan ndra dina val nr som genom. Discussion on any SPCE stock related banter for this tense Tuesday: r/SPCE January 23, and. Opinion/Rating/Report or any approach to evaluating indiv idual securities there are a of... In Zacks hypothetical portfolios at the annual return idual securities Includes ETFs & ETNs with of... Average Citius Pharmaceuticals Inc. ( CTXR ) stock price, chart, news, and... Och personuppgifter fr dessa ytterligare ndaml delays in the content been authorized, sponsored or. Beginning of each month are included ctxr stock discussion Zacks hypothetical portfolios at the beginning of each month are in. To date on the date of publication, William White did not have ( either directly or indirectly any! In contrast, Mino-Lok appears to be very useful for finding positive.... Have ( either directly or indirectly ) any positions in separately, the CTXR stock and discuss about investments. Att klicka p lnkarna `` Integritetspanel '' p vra webbplatser och appar this... That serves as a result of worse-than-expected results from its ongoing clinical trial Mino-Lok. Taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok forecast on. U.S. Food and Drug Administration ( FDA ) is the Google Privacy Policy Terms...